Boston Scientific Corporation will acquire Intera Oncology Inc., a privately held medical device company, in a move to strengthen its interventional oncology offerings.
Intera Oncology is known for its FDA-approved Intera 3000 Hepatic Artery Infusion (HAI) Pump and floxuridine, a chemotherapy drug. The deal would enhance Boston Scientific's treatment portfolio for liver-dominant metastases, particularly from colorectal cancer.
The Intera 3000 pump administers HAI therapy by delivering a continuous flow of chemotherapy directly into the liver via the hepatic artery, targeting metastatic liver tumors. The device is primarily used to treat colorectal cancer patients whose disease has spread to the liver, which occurs in about 25% of the approximately 1.4 million people in the U.S. living with colorectal cancer.
Peter Pattison, president of interventional oncology and embolization at Boston Scientific, emphasized the potential impact of the acquisition. “Liver cancer is a leading cause of cancer-related death, and we are committed to providing meaningful solutions to safely and effectively treat various forms of this disease with minimal systemic side effects and improved outcomes for patients,” he said.
Interest in HAI therapy has grown due to advancements in technique, clinical trial results, and expanding indications. Randomized trials have demonstrated that HAI therapy with the Intera 3000 pump improves tumor response, progression timelines, and overall survival compared to systemic chemotherapy. The therapy is also being investigated in Phase II and III trials for broader use in first-line and post-surgery treatments.
While financial details of the acquisition were not disclosed, Boston Scientific noted that the deal is expected to have minimal impact on adjusted earnings in 2025, with some GAAP-based dilutive effects due to acquisition-related costs.
Boston Scientific, headquartered in Marlborough, Massachusetts, has a long-standing focus on developing technologies to address critical medical needs in oncology and other specialties.
The deal is expected to close in the first half of 2025.
